Cullinan Oncology Inc. (CGEM) PT Lowered to $49 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts CGEM Hot Sheet
Price: $12.49 --0%
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
H.C. Wainwright analyst Edward White lowered the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $49.00 (from $50.00) while maintaining a Buy rating.
You May Also Be Interested In
- Cullinan Therapeutics to present drug data at ASH meeting in December
- Kraft Heinz Company (KHC) PT Raised to $26 at UBS
- Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
